Company News

New indications of IMM01 project of ImmuneOnco obtained NMPA clinical trial research license
On January 20, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (AML and MDS) and obtaining NMPA clinical trial research license.
View more
Total 56 12345678910